FIELD: biotechnology.
SUBSTANCE: invention relates to the use of a compound of the general formula (1), or its stereoisomer, or pharmaceutically acceptable salt for the preparation of a pharmaceutical composition intended for prevention of biomarker disbalance and/or recovery of biomarker balance, and reduction in harmful effects of asymptomatic progressive disseminated perfusion deficiency (blood flow deficiency) of organs or their parts, which may indicate systemic diseases, which is indicated by increased concentration of a biomarker of endothelin-1 (hereinafter – ET-1) or precursors of pre-endothelin-1 and pro-endothelin (hereinafter – big endothelin-1, Big ET-1) and/or increased activity of endothelin-1-converting enzyme (hereinafter – ECE-1) or neutral endopeptidase (hereinafter – NEP). In the general formula (1), R1 is a group of the formula (2) or (3), A is CH2; R2 and R3 are independently hydrogen; R4 and R6 are independently hydrogen or tert-butyl; R5 is naphthyl-(C1-C6)alkyl or phenyl-ethyl; R7 and R8 are independently ethyl or benzyl.
EFFECT: use of compounds of the formula (1) for the preparation of a pharmaceutical composition intended for prevention of biomarker disbalance and/or recovery of biomarker balance, and reduction in harmful effects of asymptomatic progressive disseminated perfusion deficiency (blood flow deficiency) of organs or their parts.
5 cl, 1 tbl, 1 ex
